DBT waiting for nod to set up 2 advanced institutes for research at cost of Rs.600 cr
The Department of Biotechnology (DBT) is planning to set up two advanced institutes for research including an Institute of Chronic Disease and Biotechnology.
The Department of Biotechnology (DBT) is planning to set up two advanced institutes for research including an Institute of Chronic Disease and Biotechnology to undertake, assist, promote, guide and coordinate basic and translational research of a high calibre for prevention and treatment of a broad range of diseases.
This proposal for setting up the institute at a cost of Rs.300 crore is waiting for the approval from the Planning Commission as it was forwarded as part of the proposals being considered for the current five year plan period, sources said.
Another proposal is for setting up Infectious Science and Biotechnology Institute in North East in collaboration with Translational Health Science and Technology Institute (THSTI) in North Eastern Region. The allocation sought for this institute also is Rs.300 crore.
The first institute will specially focus on treatment and prevention of stroke, heart disease, hypertension, kidney disease, and diabetes. Some focused areas of research will include advanced cell based therapies, bioengineering, imaging technology and informatics, cardiovascular; bone and joint research, clinical engineering research, clinical research, clinical studies in health and disease, molecular biology and mechanisms of disease.
The mandate of the institute will be education and training leading to Ph.D. degree, organizing workshops, seminars, symposia, training, programmes of specialized nature and to serve as a national reference centre and provide consultancy services are other activities.
The institute in the North East will primarily target to pursue an integrated strategy involving research from the gene to population and including basic to applied to clinical research addressing specific needs of infectious diseases of the region.
The focus will be on infection research, covering a range of human and animal pathogens and using an array of approaches. These include looking at the impact diseases have on populations (epidemiology); the evolution of the pathogen, the immune response that develop to fight the pathogens and prevent disease, the molecular basis of pathogen virulence, all of which contribute to better diagnosis and treatment of disease, e.g. through vaccine and drug development.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News From Pharma to Table? Direct-to-consumer pharma sales and price cuts ramp up in US
The pharmaceutical industry is witnessing a seismic shift as major companies embrace direct-to-consumer sales models and announce significant price reductions across the United States, responding to mounting pressure from the Trump administration to ta... -
News A Day in the Life of a Director of Business Development
In this Day in the Life of interview, Thomas Hauser, Director of Business Development at Tjoapack. Thomas has spent nearly 30 years in the pharmaceutical industry and describes how he still finds curiosity and excitement in the bigger picture of global... -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective.